Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: LemurHouse who wrote (226)	9/13/1998 10:16:00 PM
From: Weekapaug	Respond to of 656

Andrew, I'm have my own doubts whether I will or will not be called away? Everytime it hits the 62 area it falls back. The new drug that just finished clinical trials I questions the trials. Why? 194 people? It like a number pulled out of the sky to me. Are they saying they started with 500 and wound up with 194? 30 percent reponse rate to the remaining 194? Also, I have learned there is a big question mark as to whether FDA will approve Enbrel this week and that bows well for my options to expire worthless. It was a wild ride on friday anyways. My greatest reason for writting was I thought the 48 area appeared to be a strong support level for IMNX. I never realized I had the Sept 3rd press release almost a week in advance. Could of bought for 48 area then. Personally, I don't think IMNX will breakout until it exceeds the 72 level. Quite honestly, I'll take the 10 grand and watch if it is called. IMO opinion this a market to "buy the rumor sell the news" I am protected to 64 area anyways, since they paid me a ridiculious amount for my options. Even if I win. I will write again, since they are paying huge premiums for options. off subject- a little company with the symbol TRBO is worth watching. They are affliated with Maytag and have a new ceo from MIT running company. I'm watching it very closely and plan to visit a store with one of there machines installed to see how it works. I have never seen a company run by a MIT grad not be a sucess yet?